The effect of parenteral selenium on outcomes of mechanically ventilated patients following sepsis: a prospective randomized clinical trial

• DOI: 10.1186/s13613-015-0071-y
• Publication Date: 2015-10-01T06:43:37Z
• Authors: Legese Chelkeba; Arezoo Ahmadi; Mohammad Abdollahi; Atabak Najafi; Mohammad Hosein G...; Reza Mosaed; Mojtaba Mojtahedz...
• Keywords: Clinical endpoint; Selenium deficiency

Sepsis and septic shock is characterized by oxidative stress that mainly promotes systemic inflammation organ failure due to excessive free radical production depletion of antioxidant defenses. Therefore, we investigated the effect selenium administration on status, levels cytokines clinical outcomes.This study was a prospective randomized control trial (RCT) whereby patients received as sodium selenite (2 mg IV bolus followed 1.5 continuous infusion for 14 days) plus standard therapy. The group therapy without selenium. primary endpoint 28-day mortality. changes in mean glutathione peroxidase (GPX) activity, IL-6, IL-8 IL-10, incidence ventilator-associated pneumonia (VAP) other secondary endpoints were also recorded. VAP broken down into early late see significance each. We recorded any adverse outcomes from infusion.Over 24-month period, 54 recruited an intention treat (ITT) principle applied (selenium, n = 29; control, 25) final analysis. There no statistically significant difference between two groups mortality although it lower compared with group: 9 (31 %) versus 10 (40 (p 0.49). At day 0, GPX activity 0.185 ± 0.3 0.19 U/mL 0.9), 3, 0.52 0.5 0.17 0.2 0.02), at 7 0.55 0.24 0.032), 0.62 0.7 0.33 0.4 0.048) 1.1 1 0.89 0.70) groups, respectively. However, there differences plasma all three inflammatory point time groups. reduction occurrence (55.2 84 %, p 0.023), respectively.High-dose within frame goal-directed not resulted mortality, but increased mechanically ventilated patients. supplementation following sepsis associated reduced VAP.IRCT201212082887N4 WHO Clinical Trial Registry, August 29, 2014.